Company intelligence / Profile preview

MacroChem

Lexington, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

MacroChem advanced two main clinical topical products: EcoNail (econazole/SEPA for onychomycosis, positive Phase 1, interim Phase 2 improvement in 54%), and pexiganan (a novel topical anti-infective peptide for diabetic foot infection; two Phase 3 trials completed, NDA not approved, FDA requested additional trial and CMC changes). Both utilized the SEPA drug delivery platform. Programs did not reach commercialization.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePeptidesTopical drug deliverySynthetic peptide
Industry: Biotech

Beyond the preview

Go deeper on MacroChem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MacroChem.

Explore the full profile